U.S. Markets open in 18 mins
  • S&P Futures

    3,321.75
    -61.25 (-1.81%)
     
  • Dow Futures

    26,771.00
    -594.00 (-2.17%)
     
  • Nasdaq Futures

    11,408.00
    -180.00 (-1.55%)
     
  • Russell 2000 Futures

    1,555.10
    -33.90 (-2.13%)
     
  • Crude Oil

    37.68
    -1.89 (-4.78%)
     
  • Gold

    1,881.90
    -30.00 (-1.57%)
     
  • Silver

    23.67
    -0.90 (-3.66%)
     
  • EUR/USD

    1.1733
    -0.0057 (-0.4810%)
     
  • 10-Yr Bond

    0.7490
    -0.0290 (-3.73%)
     
  • Vix

    38.07
    +5.61 (+17.28%)
     
  • GBP/USD

    1.2943
    -0.0099 (-0.7559%)
     
  • USD/JPY

    104.3440
    -0.1500 (-0.1436%)
     
  • BTC-USD

    13,315.47
    -394.55 (-2.88%)
     
  • CMC Crypto 200

    263.60
    +2.31 (+0.88%)
     
  • FTSE 100

    5,599.64
    -129.35 (-2.26%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Investors Who Bought Champions Oncology (NASDAQ:CSBR) Shares Three Years Ago Are Now Up 231%

Simply Wall St

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. For example, the Champions Oncology, Inc. (NASDAQ:CSBR) share price has soared 231% in the last three years. Most would be happy with that. And in the last month, the share price has gained 36%.

Check out our latest analysis for Champions Oncology

Champions Oncology isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Champions Oncology's revenue trended up 27% each year over three years. That's much better than most loss-making companies. Meanwhile, the share price performance has been pretty solid at 49% compound over three years. But it does seem like the market is paying attention to strong revenue growth. That's not to say we think the share price is too high. In fact, it might be worth keeping an eye on this one.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

NasdaqCM:CSBR Income Statement, December 8th 2019
NasdaqCM:CSBR Income Statement, December 8th 2019

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Champions Oncology stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

While the broader market gained around 21% in the last year, Champions Oncology shareholders lost 22%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 3.2% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.